A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

PHASE3RecruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

May 7, 2027

Study Completion Date

June 11, 2027

Conditions

Sleep ApneaObstructiveObesity

Interventions

OTHER

placebo

placebo administered subcutaneously (SC) once a week.

DRUG

IBI362

Once-weekly injections of gradually increased doses of IBI362

Trial Locations (1)

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY